Cost effectiveness has its place, but so does common sense
BMJ
.
2014 Nov 13:349:g6759.
doi: 10.1136/bmj.g6759.
Authors
Rino Rappuoli
1
,
James Wassil
2
,
Lars Bonefeld
3
,
John Porter
3
Affiliations
1
Novartis Vaccines and Diagnostics, Siena, Italy rino.rappuoli@novartis.com.
2
Novartis Vaccines and Diagnostics, Cambridge, MA, USA.
3
Novartis Vaccines and Diagnostics Limited, Frimley, UK.
PMID:
25394622
DOI:
10.1136/bmj.g6759
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Mass Vaccination / economics*
Meningitis, Meningococcal / prevention & control*
Meningococcal Vaccines / economics*
Models, Economic*
Substances
4CMenB vaccine
Meningococcal Vaccines